• Psyence Biomedical entered a binding term sheet with PsyLabs for exclusive U.S. rights to pharmaceutical-grade ibogaine via its Texas unit.
• Texas Ibogaine Research Corporation would receive exclusive development, supply, wholesale distribution rights, subject to a definitive agreement by Nov. 30, 2026.
• PsyLabs would remain the exclusive supplier; the license includes manufacturing know-how, specifications, technical documentation for ibogaine hydrochloride.
• Consideration includes up to about USD 1.3 million in development and regulatory milestones for the first drug candidate.
• Additional economics include a low single-digit royalty on net sales, an annual exclusivity fee after first FDA approval, and margin-sharing on resale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-103733), on September 28, 2026, and is solely responsible for the information contained therein.